The Future of Worker Financial Security: The Nexus of Work and Benefits
Event information
Location
In the United States, a dominant narrative that having a job equals financial security persists, yet the majority of workers in America have jobs that do not allow them to achieve financial security. In fact, many workers lack benefits, have low earnings, and live in poverty. The type of job matters: workers with full-time, permanent positions and more robust packages of benefits do better than those without access to those options.
In a new report developed together with its
, the
Aspen Institute Financial Security Program explains how work arrangements relate to worker benefit provisions, and how both work and benefits together determine if workers will have a reasonable shot at financial security. The research explores why there are persistent disparities in financial security outcomes for low- and moderate-income (LMI) workers, especially Black and
A National Policy Blueprint To End White Supremacist Violence
April 21, 2021, 12:01 am Getty/SOPA Images/LightRocket/Stanton Sharpe
A member of the Proud Boys guards the front stage during a rally in Portland, Oregon, on September 26, 2020.
Sam Hananel
Subscribe
White supremacist violence is not new, but in recent years, it has become a primary national security threat in the United States.
1 Notions of racial superiority, hostility toward immigrants and minorities, and the myth of an embattled white majority defending its power have increasingly infiltrated mainstream American political and cultural discourse.
2 In October 2020, the U.S. Department of Homeland Security (DHS) published its annual threat assessment, identifying racially and ethnically motivated violent extremists, particularly white supremacist extremists, as “the most persistent and lethal threat in the Homeland.”
4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics
04/20/2021 | 09:00am EDT
Send by mail :
Message :
20 April 2021
LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has co-led a $10 million Seed financing round in Code Biotherapeutics, Inc. (“Code Bio” or the ”Company”), a next generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases. 4BIO actively participated in the start-up process and co-led the financing alongside UPMC Enterprises, with participation from CureDuchenne Ventures, The JDRF T1D Fund, New Enterprise Associates, and Takeda Ventures, Inc.
4Bio Capital: 4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics
20 April 2021
LONDON & BOSTON - 4BIO Capital ( 4BIO or the Group ), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has co-led a $10 million Seed financing round in Code Biotherapeutics, Inc. ( Code Bio or the Company ), a next generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases. 4BIO actively participated in the start-up process and co-led the financing alongside UPMC Enterprises, with participation from CureDuchenne Ventures, The JDRF T1D Fund, New Enterprise Associates, and Takeda Ventures, Inc.
Code Biotherapeutics Launches with $10 Million in Seed Financing to Develop Therapies for Debilitating Genetic Diseases biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.